Literature DB >> 25421152

Statins and male sexual health: a retrospective cohort analysis.

Richard Davis1, Kelly R Reveles, Sayed K Ali, Eric M Mortensen, Christopher R Frei, Ishak Mansi.   

Abstract

INTRODUCTION: Conflicting reports exist regarding the role of statins in male gonadal and sexual function. Some studies report a beneficial effect, particularly for erectile dysfunction (ED), through statins' anti-inflammatory and cardiovascular protective properties. Others suggest that statins might be associated with sexual dysfunction through negative effects on hormone levels. AIM: This study aims to compare the risk of gonadal or sexual dysfunction in statin users vs. nonusers in a single-payer healthcare system.
METHODS: This was a retrospective cohort study of all male patients (30-85 years) enrolled in the Tricare San Antonio market. Using 79 baseline characteristics, we created a propensity score-matched cohort of statin users and nonusers. The study duration was divided into a baseline period (October 1, 2003 to September 30, 2005) to describe patient baseline characteristics, and a follow-up period (October 1, 2005 to March 1, 2012) to determine patient outcomes. Statin users were defined as those prescribed a statin for ≥3 months between October 1, 2004 and September 30, 2005. MAIN OUTCOME MEASURES: Outcomes were identified as the occurrence of benign prostatic hypertrophy (BPH), ED, infertility, testicular dysfunction, or psychosexual dysfunction during the follow-up period as identified by inpatient or outpatient International Classification of Diseases, 9th Revision, Clinical Modification codes. Logistic regression was used to determine the association of statin use with patient outcomes.
RESULTS: Of 20,731 patients who met study criteria, we propensity score-matched 3,302 statin users with 3,302 nonusers. Statin use in men was not significantly associated with an increased or decreased risk of BPH (odds ratio [OR] 1.08; 95% confidence interval [CI] 0.97-1.19), ED (OR 1.01; 95% CI 0.90-1.13), infertility (OR 1.22; 95% CI 0.66-2.29), testicular dysfunction (OR 0.91; 95% CI 0.73-1.14), or psychosexual dysfunction (OR 1.03; 95% CI 0.94-1.14).
CONCLUSIONS: Statin use was not associated with increased risk of being diagnosed with gonadal or sexual dysfunction in men. Further studies using a larger sample may be needed.
© 2014 International Society for Sexual Medicine.

Entities:  

Keywords:  Benign Prostatic Hypertrophy; Erectile Dysfunction; Male Infertility; Psychosexual Dysfunction; Statin; Testicular Dysfunction

Mesh:

Substances:

Year:  2014        PMID: 25421152      PMCID: PMC4304928          DOI: 10.1111/jsm.12745

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  51 in total

Review 1.  Is decreased libido associated with the use of HMG-CoA-reductase inhibitors?

Authors:  L de Graaf; A H P M Brouwers; W L Diemont
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

2.  Statins and erectile dysfunction: results of a case/non-case study using the French Pharmacovigilance System Database.

Authors:  Catherine Do; Eric Huyghe; Maryse Lapeyre-Mestre; Jean Louis Montastruc; Haleh Bagheri
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

3.  The effect of statin therapy on testosterone levels in subjects consulting for erectile dysfunction.

Authors:  Giovanni Corona; Valentina Boddi; Giancarlo Balercia; Giulia Rastrelli; Giulia De Vita; Alessandra Sforza; Gianni Forti; Edoardo Mannucci; Mario Maggi
Journal:  J Sex Med       Date:  2010-02-05       Impact factor: 3.802

4.  Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction.

Authors:  E Bruckert; P Giral; H M Heshmati; G Turpin
Journal:  J Clin Pharm Ther       Date:  1996-04       Impact factor: 2.512

5.  Effect of atorvastatin on erectile functions in comparison with regular tadalafil use. A prospective single-blind study.

Authors:  Mehmet İlker Gokce; Ömer Gülpınar; Erdem Öztürk; Sadi Güleç; Önder Yaman
Journal:  Int Urol Nephrol       Date:  2012-01-18       Impact factor: 2.370

6.  Statins and musculoskeletal conditions, arthropathies, and injuries.

Authors:  Ishak Mansi; Christopher R Frei; Mary Jo Pugh; Una Makris; Eric M Mortensen
Journal:  JAMA Intern Med       Date:  2013-07-22       Impact factor: 21.873

7.  Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation.

Authors:  Erin A Saltzman; Andre T Guay; Jerilynn Jacobson
Journal:  J Urol       Date:  2004-07       Impact factor: 7.450

8.  Effects of rosuvastatin on nitric oxide-dependent function in aorta and corpus cavernosum of diabetic mice: relationship to cholesterol biosynthesis pathway inhibition and lipid lowering.

Authors:  Matthew R Nangle; Mary A Cotter; Norman E Cameron
Journal:  Diabetes       Date:  2003-09       Impact factor: 9.461

9.  Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms.

Authors:  Michele M Castro; Elen Rizzi; Ricardo R Rascado; Sabrina Nagassaki; Lusiane M Bendhack; Jose E Tanus-Santos
Journal:  Eur J Pharmacol       Date:  2004-09-13       Impact factor: 4.432

10.  Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement.

Authors:  Ian W Mills; Anna Crossland; Anup Patel; Henrikas Ramonas
Journal:  Eur Urol       Date:  2007-02-20       Impact factor: 20.096

View more
  4 in total

1.  Do Statins Increase the Risk of Esophageal Conditions? Findings from Four Propensity Score-Matched Analyses.

Authors:  Ioana Smith; Robert Schmidt; Ethan A Halm; Ishak A Mansi
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

2.  The effect of atorvastatin on penile intracavernosal pressure and cavernosal morphology in normocholesterolemic rats.

Authors:  Mustafa Suat Bolat; Mustafa Bakırtaş; Fatih Fırat; Ekrem Akdeniz; Önder Çınar; Fikret Erdemir
Journal:  Turk J Urol       Date:  2018-08-31

3.  The effects of statins on benign prostatic hyperplasia and the lower urinary tract symptoms: A Meta-analysis.

Authors:  Xuesong Yang; Qiang Zhang; Guo Jiang; Junbo Liu; Chaofan Xie; Shu Cui; Tao Wu
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

Review 4.  The Investigative Role of Statins in Ameliorating Lower Urinary Tract Symptoms (LUTS): A Systematic Review.

Authors:  Giorgio Ivan Russo; Gaetano Larganà; Arcangelo Sebastianelli; Andrea Cocci; Marina Di Mauro; Ilenia Rapallo; Giuseppe Morgia; Matteo Mario Morgia; Sandro La Vignera; Rosita Condorelli; Aldo E Calogero; Iacopo Olivotto; Simone Morselli; Sergio Serni; Mauro Gacci
Journal:  J Clin Med       Date:  2021-01-22       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.